Vesicular Monoamine Transport Proteins
"Vesicular Monoamine Transport Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of vesicular amine transporter proteins that catalyze the transport and storage of CATECHOLAMINES and indolamines into SECRETORY VESICLES.
| Descriptor ID |
D050493
|
| MeSH Number(s) |
D12.776.157.530.450.162.887.500.500 D12.776.157.530.562.750.500.500 D12.776.543.585.450.162.887.500.500 D12.776.543.585.562.750.500.500
|
| Concept/Terms |
Vesicular Monoamine Transport Proteins- Vesicular Monoamine Transport Proteins
- Vesicular Monoamine Transporter Proteins
- Monoamine Vesicular Transporter
- Vesicular Transporter, Monoamine
- Vesicular Monoamine Transporter
- Monoamine Transporter, Vesicular
- Monoamine Transporters, Vesicular
- Vesicular Monoamine Transporters
- Monoamine Vesicular Transport Proteins
Vesicular Monoamine Transporter 1- Vesicular Monoamine Transporter 1
- VMAT-1 Vesicular Monoamine Transporter
- VMAT 1 Vesicular Monoamine Transporter
- Chromaffin Granule Amine Transporter
|
Below are MeSH descriptors whose meaning is more general than "Vesicular Monoamine Transport Proteins".
Below are MeSH descriptors whose meaning is more specific than "Vesicular Monoamine Transport Proteins".
This graph shows the total number of publications written about "Vesicular Monoamine Transport Proteins" by people in this website by year, and whether "Vesicular Monoamine Transport Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 4 | 2 | 6 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vesicular Monoamine Transport Proteins" by people in Profiles.
-
Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease. Biochem Biophys Res Commun. 2019 05 28; 513(2):306-312.
-
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12:1215-1238.
-
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec; 78(9):1344-1350.
-
Deletions at SLC18A1 increased the risk of CRC and lower SLC18A1 expression associated with poor CRC outcome. Carcinogenesis. 2017 10 26; 38(11):1057-1062.
-
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. J Comp Eff Res. 2018 02; 7(2):135-148.
-
Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017 Sep/Oct; 78(8):1136-1147.
-
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):53-60.
-
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):69-76.